ライフサイエンスコーパス: hepatic fibrosis

1 e currently no therapies to directly inhibit hepatic fibrosis.

2 and are considered a key factor in promoting hepatic fibrosis.

3 al chemokine signaling pathways also promote hepatic fibrosis.

4 FibroTest is an indirect serum marker of hepatic fibrosis.

5 olic fatty liver disease (NAFLD) may lead to hepatic fibrosis.

6 reas Vdr knockout mice spontaneously develop hepatic fibrosis.

7 n a rat model of thioacetamide (TAA)-induced hepatic fibrosis.

8 TGF-beta antagonism can improve pre-existing hepatic fibrosis.

9 e aimed to investigate the role of SEMA7A in hepatic fibrosis.

10 n D on initiation rather than progression of hepatic fibrosis.

11 is C virus (HCV) infection is complicated by hepatic fibrosis.

12 se, results in biliary tract obstruction and hepatic fibrosis.

13 Myofibroblasts produce the fibrous scar in hepatic fibrosis.

14 creased intrahepatic biliary mass (IBDM) and hepatic fibrosis.

15 thelial cells (LSECs), precedes the onset of hepatic fibrosis.

16 gesting a potential therapeutic approach for hepatic fibrosis.

17 ed the contributory role of NOX1 and NOX2 in hepatic fibrosis.

18 cytes do not undergo EMT in murine models of hepatic fibrosis.

19 matory cytokine production, cholestasis, and hepatic fibrosis.

20 ased in the two experimental mouse models of hepatic fibrosis.

21 hat Egr-1 is required for the development of hepatic fibrosis.

22 llagen deposition and histologically visible hepatic fibrosis.

23 the proinflammatory milieu characteristic of hepatic fibrosis.

24 to play critical roles in the development of hepatic fibrosis.

25 s, and finally a focus on matrix biology and hepatic fibrosis.

26 actant protein (MCP)-1, MCP-2, and MCP-3, in hepatic fibrosis.

27 epresent an effective therapeutic target for hepatic fibrosis.

28 nts per day, was associated with less severe hepatic fibrosis.

29 association between caffeine consumption and hepatic fibrosis.

30 omotes HSC chemotaxis and the development of hepatic fibrosis.

31 hogenic role for IL-15-driven immunomediated hepatic fibrosis.

32 role of PI3K in HSCs using a rodent model of hepatic fibrosis.

33 ther CD73 plays a role in the development of hepatic fibrosis.

34 Capillarization precedes hepatic fibrosis.

35 kade of adenosine receptors may help prevent hepatic fibrosis.

36 2A) receptors, plays a role in toxin-induced hepatic fibrosis.

37 sease spectrum in humans, including bridging hepatic fibrosis.

38 prior interferon nonresponders with advanced hepatic fibrosis.

39 ation but also contributes to progression of hepatic fibrosis.

40 ha signaling could alter the pathogenesis of hepatic fibrosis.

41 rdingly, Myd88-deficient mice have decreased hepatic fibrosis.

42 the natural history and future treatment of hepatic fibrosis.

43 posed for the non-invasive identification of hepatic fibrosis.

44 (IFN-gamma 1b) for the treatment of advanced hepatic fibrosis.

45 to identify factors associated with advanced hepatic fibrosis.

46 utic antifibrotic agent for the treatment of hepatic fibrosis.

47 iron overload in association with increased hepatic fibrosis.

48 apy may be a promising approach for treating hepatic fibrosis.

49 ein had significant shared gene effects with hepatic fibrosis.

50 biliary contribution to cholestasis-induced hepatic fibrosis.

51 /interleukin-9 (IL-9) in the pathogenesis of hepatic fibrosis.

52 nses and may provide important insights into hepatic fibrosis.

53 chanistically link congestive hepatopathy to hepatic fibrosis.

54 ation of glucocorticoids, and predisposes to hepatic fibrosis.

55 thrombosis and strain, which in turn promote hepatic fibrosis.

56 s, and this result is an indirect measure of hepatic fibrosis.

57 ographics, lifestyle, metabolic factors, and hepatic fibrosis.

58 s erythematosus, ankylosing spondylitis, and hepatic fibrosis.

59 hromatosis and this correlates strongly with hepatic fibrosis.

60 red with nonblacks, blacks had more advanced hepatic fibrosis (3.6 +/- 2.7 versus 2.1 +/- 2.4, P = 0.

61 less (P = .030) than that for patients with hepatic fibrosis (4.16 kPa).

62 flare values than those with no significant hepatic fibrosis (9.62+/-1.99 photon counts/ms vs. 6.97+

63 ted postnatal growth would lead to increased hepatic fibrosis (a pathological marker of liver dysfunc

64 V) infection is characterized by progressive hepatic fibrosis, a process dependent on monocyte recrui

65 In HIV/HCV-coinfected women, hepatic fibrosis accelerates with reproductive aging.

66 Strong associations with advanced hepatic fibrosis (adjusted odds ratio [95% confidence in

67 Decreased hepatic fibrosis after chronic CCl(4) administration in

68 and is an independent predictor of advanced hepatic fibrosis among patients with NAFLD.

69 votal event in initiation and progression of hepatic fibrosis and a major contributor to collagen dep

70 ated with an increased risk of both advanced hepatic fibrosis and advanced hepatic inflammatory activ

71 nction contributes to immunologic changes in hepatic fibrosis and affects the pathologic inflammatory

72 agonist can diminish and potentially reverse hepatic fibrosis and also reduce the number and size of

73 njury that were consistent with decreases in hepatic fibrosis and biliary ductal damage relative to t

74 The risk of hepatic fibrosis and cirrhosis in hereditary hemochromat

75 ression was dramatically reduced in advanced hepatic fibrosis and cirrhosis in humans.

76 Nogo-B (reticulon 4B) accentuates hepatic fibrosis and cirrhosis, but the mechanism remain

77 se studies support a central role of CCN2 in hepatic fibrosis and demonstrate a role of the microenvi

78 nt role of liver biopsy in the assessment of hepatic fibrosis and discusses the role of the newer non

79 The proteins identified may help to assess hepatic fibrosis and eliminate the need for invasive liv

80 a deleterious role of Th9/IL-9 in increasing hepatic fibrosis and exacerbating disease endpoints, ind

81 ed their potential as noninvasive markers of hepatic fibrosis and fibrosis progression in African-Ame

82 a robust readout to screen for regulators of hepatic fibrosis and have identified a novel antifibroti

83 stablish lifelong chronic infections causing hepatic fibrosis and hepatocellular carcinoma.

84 indicator associated with the progression to hepatic fibrosis and hepatocellular carcinoma.

85 rest in uncovering the mechanisms underlying hepatic fibrosis and its resolution.

86 rus infection is associated with progressive hepatic fibrosis and liver cancer.

87 ficient mice displayed substantially reduced hepatic fibrosis and macrophage infiltration.

88 SVR reduces the rate of hepatic fibrosis and other disease-related complications

89 Increasing evidence suggests that hepatic fibrosis and pathological angiogenesis are inter

90 cultures correlated with protection against hepatic fibrosis and portal hypertension.

91 Hepatic fibrosis and portal pressure were significantly

92 of childhood, is characterized by congenital hepatic fibrosis and progressive cystic degeneration of

93 of childhood, is characterized by congenital hepatic fibrosis and progressive cystic degeneration of

94 nking is a remarkable feature of progressing hepatic fibrosis and represents an important therapeutic

95 Hepatic fibrosis and ROS generation were attenuated in b

96 We investigated the heritability of hepatic fibrosis and steatosis in a community-dwelling t

97 (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively.

98 s, plays a major role in the pathogenesis of hepatic fibrosis and that inhibition of adenosine produc

99 simultaneously, yet independently, directed hepatic fibrosis and the compensatory proliferation of h

100 a negative regulator of both CCl(4)-induced hepatic fibrosis and the oval cell response.

101 rypsin Z (ATZ) variant inside cells, causing hepatic fibrosis and/or carcinogenesis by a gain-of-toxi

102 Thirty-three subjects had minimal hepatic fibrosis, and 19 developed bridging fibrosis or

103 , number of bile infarcts, serum ALT values, hepatic fibrosis, and animal survival were also improved

104 chemokine inhibitor 35k efficiently reduced hepatic fibrosis, and CCR1- and CCR5-deficient mice disp

105 om nonalcoholic steatohepatitis, for staging hepatic fibrosis, and for identifying NAFLD in patients

106 e, higher initial HCV RNA level, more severe hepatic fibrosis, and higher body weight.

107 mputational approaches to drug discovery for hepatic fibrosis, and identify C1QTNF2 as a potential me

108 HSCs) in response to injury is a key step in hepatic fibrosis, and is characterized by trans-differen

109 60% reductions in liver weight, cyst volume, hepatic fibrosis, and mitotic indices.

110 Little is known about the heritability of hepatic fibrosis, and the heritability of hepatic steato

111 he relationship between portal inflammation, hepatic fibrosis, and the metabolic syndrome in pediatri

112 ansforming growth factor beta (TGF-beta) and hepatic fibrosis are hallmarks of hepatitis C virus (HCV

113 provides evidence that hepatic steatosis and hepatic fibrosis are heritable traits.

114 Thus, angiogenesis and hepatic fibrosis are mutually stimulatory, such that fib

115 atic steatosis, yet the risks for developing hepatic fibrosis are poorly understood.

116 leads to hepatocyte dysfunction, death, and hepatic fibrosis are still unclear.

117 RPKD and ADPKD, respectively) and congenital hepatic fibrosis as well as in the PKC rat model of ARPK

118 f green tea extract prevented CCl(4)-induced hepatic fibrosis, as evidenced by a decreased hydroxypro

119 tors or siRNA can prevent the progression of hepatic fibrosis, as yet no evidence has been provided t

120 ction was strongly associated with increased hepatic fibrosis at 1 year, and MMF use appears to have

121 l (PZQ) and performed ultrasound to quantify hepatic fibrosis at baseline and 12 months after PZQ tre

122 hypothesis that adenosine receptors promote hepatic fibrosis, at least in part, via direct stimulati

123 Neutralization of IL-9 in mice ameliorated hepatic fibrosis, attenuated the activation of hepatic s

124 ; P < 1.1 x 10(-11)) and the heritability of hepatic fibrosis (based on liver stiffness) was 0.5 (95%

125 We investigated changes in hepatic fibrosis, based on transient elastography (TE),

126 CCl4 -cirrhotic rats was linked to decreased hepatic fibrosis, but not in BDL rats, in which the main

127 nd the adenosine A2A receptor play a role in hepatic fibrosis by a mechanism that has been proposed t

128 evel in the liver and a reduced incidence of hepatic fibrosis by histological observations.

129 between alcohol use categories and advanced hepatic fibrosis, by HIV and chronic HCV status.

130 Hepatic fibrosis can also develop from metabolic liver d

131 The presence of hepatic fibrosis can be assessed with good discriminatio

132 Hepatic fibrosis can be reversed by inducing selective a

133 for nonalcoholic steatohepatitis (NASH) and hepatic fibrosis, can be used for patients with psoriasi

134 In some contexts (e.g., hepatic fibrosis), changes to the ECM are well recognize

135 Congenital hepatic fibrosis (CHF) is a disease of the biliary epith

136 ss of fibrocystin function causes congenital hepatic fibrosis (CHF), Caroli disease (CD), and autosom

137 bolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure.

138 s, which progressively leads to cholestasis, hepatic fibrosis, cirrhosis, and eventually liver failur

139 Hepatic fibrosis/cirrhosis was present in 25 of 103 pati

140 and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.

141 a NASH phenotype in OLETFs characterized by hepatic fibrosis (collagen 1alpha1 mRNA and hydroxyproli

142 Hepatic fibrosis, collagen content, inflammatory cytokin

143 Finally, TANGO1(+/-) mice displayed less hepatic fibrosis compared to WT mice in two separate mur

144 17A were significantly elevated in mice with hepatic fibrosis compared with controls.

145 steatohepatitis are at an increased risk of hepatic fibrosis compared with premenopausal women.

146 Hepatic fibrosis develops as a response to chronic liver

147 Thus, in patients with advanced hepatic fibrosis due to HCV infection, pretreatment HCV-

148 R-200b axis may be key for the management of hepatic fibrosis during the progression of PSC.

149 cal and laboratory features predicted severe hepatic fibrosis equally well in AA and CA patients with

150 ant towards developing strategies to prevent hepatic fibrosis especially following HCV recurrence in

151 ween total testosterone and risk of advanced hepatic fibrosis (F3 and F3/F4) and inflammatory activit

152 Baseline advanced hepatic fibrosis (FIB-4 score >3.25) (HR, 5.45 [CI, 3.79

153 tuberculosis and in granuloma formation and hepatic fibrosis following chronic percutaneous infectio

154 (IL)-10, IL-12p40, and IL-13Ralpha2 regulate hepatic fibrosis following infection with the helminth p

155 Stellate cell activation leads to hepatic fibrosis; furthermore, their activation is suppr

156 ferase to platelet ratio index score >/=1.5, hepatic fibrosis >/=F3, and hepatic steatosis >/=S2 were

157 The prospect of reversing hepatic fibrosis has generated great interest now that b

158 d in chronic hepatitis B (CHB) patients with hepatic fibrosis, HBV-associated liver cirrhosis (LC) pa

159 ng-term HBV DNA suppression and reduction in hepatic fibrosis, hepatic decompensation, and liver-rela

160 tiple lines of evidence demonstrate that the hepatic fibrosis/hepatic stellate cell activation may be

161 congestion (congestive hepatopathy) leads to hepatic fibrosis; however, the mechanisms involved in th

162 R-200b is associated with the progression of hepatic fibrosis; however, the role of the GnRH/GnRHR1/m

163 sistent liver mononuclear cell infiltration, hepatic fibrosis, hypergammaglobulinemia, anti-nuclear a

164 (CBZ) decreased the hepatic load of ATZ and hepatic fibrosis in a mouse model of AT deficiency-assoc

165 y may have promise as noninvasive markers of hepatic fibrosis in a predominantly white HCV genotype 1

166 f being used to estimate the degree of early hepatic fibrosis in a rat model.

167 imaging techniques to more accurately stage hepatic fibrosis in a rat model.

168 erated postnatal catch-up growth caused more hepatic fibrosis in adulthood, which was associated with

169 siglitazone altered liver enzymes and caused hepatic fibrosis in APOE4 mice.

170 antagonist reduced biliary proliferation and hepatic fibrosis in BDL WT and Mdr2(-/-) mice.

171 The gradual accumulation of hepatic fibrosis in chronic liver disease results in cli

172 lls, isolated from wild type livers restored hepatic fibrosis in Cxcr6(-/-) mice upon experimental st

173 Both NOX1 and NOX2 have an important role in hepatic fibrosis in endogenous liver cells, including HS

174 ories were strongly associated with advanced hepatic fibrosis in HIV/HCV-coinfected patients.

175 ing the mechanisms of schistosome-associated hepatic fibrosis in humans, and few biomarkers for risk

176 loride (CCl(4))-induced oxidative stress and hepatic fibrosis in male ICR mice.

177 on to augment TGFbeta production and promote hepatic fibrosis in mice and to induce a profibrogenic p

178 against CCl(4)-induced oxidative stress and hepatic fibrosis in mice by inhibiting oxidative damage

179 HSC retinoid homeostasis and inhibited hepatic fibrosis in mice with NASH.

180 ediators interact to slow the progression of hepatic fibrosis in mice with schistosomiasis.

181 d by genetic labeling does not contribute to hepatic fibrosis in mice.

182 so attenuated the development of BDL-induced hepatic fibrosis in mice.

183 d by gross pathology and histopathology, and hepatic fibrosis in patients was examined with ultrasoun

184 We aimed to describe congenital hepatic fibrosis in patients with ARPKD, confirmed by de

185 consumption (CC) is associated with reduced hepatic fibrosis in patients with chronic liver diseases

186 toring of the development and progression of hepatic fibrosis in patients with psoriasis receiving lo

187 uggesting the development and progression of hepatic fibrosis in patients with psoriasis receiving lo

188 ient elastography (VCTE) in the detection of hepatic fibrosis in patients with severe to morbid obesi

189 rotein 10 [IP-10]) have been associated with hepatic fibrosis in predominantly white hepatitis C viru

190 H/GnRHR1/miR-200b axis in the development of hepatic fibrosis in PSC is unknown.

191 tial pharmaceutical intervention to decrease hepatic fibrosis in response to ethanol.

192 1(Cre)/Dyn2K44A(fl/fl) mice showed increased hepatic fibrosis in response to liver injury.

193 a promising biomarker for assessing risk of hepatic fibrosis in schistosomiasis and, potentially, ot

194 The presence and severity of hepatic fibrosis in subjects with NAFLD was determined b

195 dark therapy or melatonin administration on hepatic fibrosis in the multidrug resistance gene 2-knoc

196 Fructose consumption predicts increased hepatic fibrosis in those with nonalcoholic fatty liver

197 n individuals annually and cause significant hepatic fibrosis in up to 20%.

198 a model of bile duct ligation (BDL)-induced hepatic fibrosis in vivo, and isolated liver-derived cel

199 brotic genes in vitro and decreased IBDM and hepatic fibrosis in vivo.

200 ch HIV/HCV group, the prevalence of advanced hepatic fibrosis increased as alcohol use category incre

201 patitis C virus (HCV)-related progression of hepatic fibrosis, increases HCV persistence, and decreas

202 of diabetes was associated with more severe hepatic fibrosis independent of iron loading, male gende

203 At 12 mo, hepatic fibrosis, indexes of inflammation, oxidative str

204 onstrates that 1D11 can reverse pre-existing hepatic fibrosis induced by extended dosing of TAA.

205 Hepatic fibrosis is a common outcome of a variety of chr

206 Hepatic fibrosis is a global health problem currently wi

207 Severe hepatic fibrosis is associated with a high risk of early

208 Hepatic fibrosis is associated with an overproduction of

209 Hepatic fibrosis is characterized by both intense intrah

210 Hepatic fibrosis is considered as a physiological wound-

211 Severity of hepatic fibrosis is greater in postmenopausal than in pr

212 Hepatic fibrosis is marked by activation of hepatic stel

213 Originally considered to be irreversible, hepatic fibrosis is now known to be a dynamic process wi

214 Hepatic fibrosis is the final common pathway for many di

215 Hepatic fibrosis is the net accumulation of matrix tissu

216 Hepatic fibrosis is the primary mediator of disease due

217 er this variant promotes clinically relevant hepatic fibrosis is unknown.

218 re independently associated with less severe hepatic fibrosis (Ishak >or= 3 versus <3).

219 effects of supplementation with synbiotic on hepatic fibrosis, liver enzymes, and inflammatory marker

220 Plasma cholesterol (P < 0.001), histological hepatic fibrosis, liver hydroxyproline content (P = 0.00

221 in the generation of T regulatory cells, in hepatic fibrosis LSECs induce an immunogenic T cell phen

222 y fat fraction >/=5%), and 8.2% (10/122) had hepatic fibrosis (magnetic resonance elastography >/=3 k

223 cellent diagnostic performance for assessing hepatic fibrosis; MR elastography was more technically r

224 ersus 56.0%; non-CC, 44.1% versus 16.2%) and hepatic fibrosis (noncirrhotic, 63.3% versus 41.9%; cirr

225 Advanced hepatic fibrosis, obesity, and steatosis are factors ass

226 Hepatic fibrosis occurs during most chronic liver diseas

227 Hepatic fibrosis occurs during the progression of primar

228 N was independently associated with advanced hepatic fibrosis (odds ratio [OR], 1.66; 95% confidence

229 rphometry can provide precise measurement of hepatic fibrosis on a continuous scale.

230 ) was independently associated with advanced hepatic fibrosis on multiple regression analysis after a

231 We found that hepatic fibrosis onset can be partially attributed to th

232 03, following histological proof of advanced hepatic fibrosis or cirrhosis (Ishak score 4-6).

233 Finding at least moderate hepatic fibrosis or gastroesophageal varices (GOV) at oe

234 al [CI]: 1.014-1.082, P = 0.005), and severe hepatic fibrosis (OR 2.177, 95% CI: 1.043-4.542, P = 0.0

235 s the only independent predictor of advanced hepatic fibrosis (OR 4.37, 95% CI 1.41-13.54 [P = 0.010]

236 ce have unprecedented degree and rapidity of hepatic fibrosis progression and clinically relevant cir

237 versible cross-linking is thought to promote hepatic fibrosis progression and limit its reversibility

238 to support the hypothesis that HCV enhances hepatic fibrosis progression through the generation of R

239 ence that HIV and HCV independently regulate hepatic fibrosis progression through the generation of R

240 TG2 and TG activity are up-regulated during hepatic fibrosis progression, but do not contribute to f

241 HIV/HCV coinfection leads to accelerated hepatic fibrosis progression, with higher rates of cirrh

242 ; however, its use had no apparent impact on hepatic fibrosis progression.

243 oxidase (LOX) to collagen stabilization and hepatic fibrosis progression/reversalin vivousing chroni

244 negative relationship between coffee CC and hepatic fibrosis (r = -0.215; P = 0.035).

245 Hepatic fibrosis reduced the correlation between biopsy

246 bilobar disease and/or associated congenital hepatic fibrosis remains challenging.

247 Induction of substantial hepatic fibrosis requires 12 weeks of CCl4 administratio

248 Hepatic fibrosis results from chronic hepatic injury, an

249 ese data suggest that schistosome-associated hepatic fibrosis results, in part, from excessive inhibi

250 icant association of a higher NASH FibroSure hepatic fibrosis score in women (Spearman rho = 0.21; P

251 The rate of hepatic fibrosis score progression (RFSP) in predicting

252 rferon-stimulated gene levels in T cells and hepatic fibrosis score.

253 otoxic effects, and monitor for worsening of hepatic fibrosis scores during MTX therapy.

254 r caffeine and whether there is an effect on hepatic fibrosis specifically.

255 dence of clinical outcomes based on baseline hepatic fibrosis stage (classification range, F0-F4): F0

256 Histological specimens were scored for hepatic fibrosis stage according to the METAVIR scoring

257 hat the DR was significantly correlated with hepatic fibrosis stage and biliary taurocholate levels.

258 The hepatic fibrosis stage was assessed histologically by us

259 cohort of patients with HIV/HCV coinfection, hepatic fibrosis stage was independently associated with

260 y in the detection of clinically significant hepatic fibrosis (stage F2-F4) (mean area under the curv

261 of HCV in persons with rapid progression of hepatic fibrosis, suggesting higher turnover of infected

262 ents with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to inte

263 d an inflammatory cell infiltration and mild hepatic fibrosis that was prevented by treatment with ir

264 hronic liver disease result from progressive hepatic fibrosis, the available diagnostic tests used in

265 h factor beta (TGF-beta) plays a key role in hepatic fibrosis, the final common pathway for a variety

266 al adhesion complexes in HSCs is pivotal for hepatic fibrosis therapy, now that small adiponectin-lik

267 hol dehydrogenase (ADH2) alleles may promote hepatic fibrosis through increased accumulation of aceta

268 HSCs mediate hepatic fibrosis through their activation from a quiesce

269 ratio index (APRI) as a surrogate marker of hepatic fibrosis to characterize liver disease in the Mu

270 tractable CCl(4)-induced model of reversible hepatic fibrosis to identify and characterize the macrop

271 and megakaryocytic precursors, resulting in hepatic fibrosis, transient postnatal thrombocytosis, an

272 Although hepatic fibrosis typically follows chronic inflammation,

273 Moderate ethanol consumption exacerbates hepatic fibrosis upon exposure to CCl4.

274 ectin and AMPK inhibit HSC proliferation and hepatic fibrosis via multiple molecular mechanisms.

275 lecule in the development and progression of hepatic fibrosis via the activation of hepatic stellate

276 Moreover, hepatic fibrosis was also evident in these animals in re

277 reactive oxygen species (ROS) generation and hepatic fibrosis was assessed in vitro and in vivo using

278 Advanced hepatic fibrosis was defined by FIB-4 index >3.25.

279 Furthermore, the degree of hepatic fibrosis was enhanced in MCD-fed AnxA1 KO mice,

280 After chronic CCl(4) exposure, hepatic fibrosis was established in both genotypes; howe

281 Histopathologic hepatic fibrosis was graded qualitatively by using the I

282 Hepatic fibrosis was induced by bile duct ligation (BDL)

283 Hepatic fibrosis was induced by CCl(4) or TAA treatment

284 Hepatic fibrosis was induced during 12 weeks of intraper

285 Hepatic fibrosis was induced in wild-type (WT) mice, NOX

286 For each alcohol use category, advanced hepatic fibrosis was more common among HIV-infected than

287 gadoxetate disodium in the setting of active hepatic fibrosis was not associated with increased fibro

288 tosis and a more-robust NAFLD phenotype with hepatic fibrosis was observed at 12 months in OffOb-OD.

289 Advanced hepatic fibrosis was present at low levels of alcohol co

290 Hepatic fibrosis was scored using the Ishak (0-6) scale;

291 Patients with ARPKD and congenital hepatic fibrosis were evaluated at the National Institut

292 Forty four candidate biomarkers for hepatic fibrosis were identified of which 20 were novel

293 ected mice from carbon tetrachloride-induced hepatic fibrosis, whereas global loss of beta(3), beta(5

294 administration for 8 weeks induced extensive hepatic fibrosis, whereupon 1D11 dosing was initiated an

295 ith CCl4 were susceptible to the development hepatic fibrosis with higher levels of ILK, pGSK3b, and

296 n a prospective study of chronic HCV-related hepatic fibrosis with little or no fibrosis at first bio

297 ance imaging-proton density fat fraction and hepatic fibrosis with magnetic resonance elastography.

298 Two patients had hepatic fibrosis, with 1 showing a sinusoidal pattern of

299 ads in some cases to development of advanced hepatic fibrosis, with complications including liver fai

300 TFF-fed L-FABP(-/-) mice exhibited decreased hepatic fibrosis, with reduced expression of fibrogenic